Think

Search This Blog

In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

July 08, 2021

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

By REBECCA ROBBINS and PAM BELLUCK | NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Patients Hate ‘Forever’ Drugs. Is Wegovy Different?

The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication. Gina Kolata | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

Following Measles Outbreaks, Officials Grow Wary of Renewed Threat

Cases this year have already topped the total in 2023. Unvaccinated travelers account for most infections. Apoorva Mandavilli | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug

Comments

Post a Comment